Our Products News
-
Ribo Showcases New Clinical Data from Leading siRNA Programs at ESC 2025, Underscoring Significant Progress and Achievements in Advancing Cardiovascular TherapiesRibo and Ribocure Pharmaceuticals AB presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress in Madrid, Spain, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline.September 10, 2025 -
Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaRibo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaFebruary 26, 2025 -
First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimFirst Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimJanuary 10, 2025 -
Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024August 31, 2024 -
Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNAInnovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.April 8, 2024 -
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesBoehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesJanuary 3, 2024